Natera NTRA 深 沪
等待开盘 08-10 09:30:00 美东时间
322.10
+56.720
+21.37%
华盛通- 最 高323.0099
- 今 开320.90
- 成交量 333.78万股
- 最 低 263.55
- 昨 收 265.38
- 总市值 3102.27万
- 52周最高 323.0099
- 市盈率 静 --
- 换手率 3465.57%
- 52周最低 156.71
- 委 比 60.85%
- 总股本 9.63万
- 历史最高 323.0099
- 量 比 2.50
- 振 幅 22.41%
- 历史最低 1.10
- 每 手 1
- 风险率 32.48%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Tempus AI Makes Billion-Dollar Bet on the Future of Cancer Monitoring
Tempus AI acquires Personalis for $1.5B to target the $20B MRD cancer monitoring market. Get full deal details and analysis.
07-22 02:52
Natera Partners With Aveta On Late-Stage Head And Neck Cancer Trial
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, and Aveta Biomics, Inc., a clinical-stage immuno-oncology company advancing first-in-class oral immunotherapies for solid tumors,
06-29 18:12
Natera Secures Landmark Japan Nod For Signatera In Colorectal Cancer
Natera won Japan approval for Signatera in colorectal cancer, paving the way for a commercial launch by 2026.
06-25 02:14
Natera Enhances Its Panorama Non-Invasive Prenatal Test, Adding Clinically-Validated Performance Data
Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced a major enhancement to its Panorama non-invasive prenatal test (NIPT). Powered by the company's novel
05-26 18:09
Natera Positioned To Capture Growing $20 Billion MRD Opportunity-Analyst
William Blair starts Natera coverage, citing MRD growth potential, strong moat, and diversified pipeline supporting long-term outlook.
04-15 02:30
Judge Hands Natera 30% Ongoing Royalty In MRD Patent Battle
Natera rises after a Delaware court grants a 30% ongoing royalty in its MRD patent battle with ArcherDx and Invitae.
04-09 20:19
Natera's Signatera Data Suggests Select Breast Cancer Patients Could Skip Surgery
Natera Signatera data shows MRD-guided therapy may reduce surgery in older breast cancer patients; analysts maintain bullish outlook.
04-01 00:48
Earnings Scheduled For February 26, 2026
Companies Reporting Before The Bell • Enovis (NYSE:ENOV) is estimated to report...
02-26 19:11
Natera Completes Enrollment In ACES-EMB Study Evaluating Prospera Heart Test
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the completion of enrollment in ACES-EMB, the first randomized-controlled trial evaluating whether Natera's Prospera
01-28 21:06
Natera Advances Molecular Residual Disease-Based Risk Stratification With New Multi-Model
Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing and precision medicine, today announced an advancement in molecular residual disease (MRD)-based risk stratification that is expected to
01-13 21:10
